Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)

Phase 2 Completed 55 enrolled Eiger BioPharmaceuticals Ankara University · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

An Open-label, Dose-ranging Study to Evaluate the Safety and Efficacy of Lonafarnib with Ritonavir Boosting +/- Peginterferon alfa-2a in Patients Chronically Infected with Delta Hepatitis (HDV) (LOWR-2).

Timeline

Start: 2014-12
Primary completion: 2017-04-18
Completion: 2017-06-15

Publications

Yurdaydin C, Keskin O, Yurdcu E, Caliskan A, Onem S, Karakaya F, Kalkan C, Karatayli E, Karatayli S, Choong I, Apelian D, Koh C, Heller T, Idilman R, Bozdayi AM, Glenn JS. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis. Hepatology. 2022 Jun;75(6):1551-1565. doi: 10.1002/hep.32259. Epub 2021 Dec 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lonafarnib	Small molecule	25 mg	Oral
Subject	Lonafarnib	Small molecule	50 mg	Oral
Subject	Lonafarnib	Small molecule	75 mg	Oral
Subject	Lonafarnib	Small molecule	100 mg	Oral
Subject	Lonafarnib	Small molecule	150 mg	Oral
Subject	Peginterferon alfa-2a	Protein / enzyme biologic	180 ug	—
Background	Ritonavir	Other / unclassified	50 mg	—
Background	Ritonavir	Other / unclassified	100 mg	—

Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)

Summary

Timeline

Publications

Drugs

Indications